GlassScriptPhysician profile
Artemio Perez
NPI 1821299926
$1,663.73
in general payments reported to CMS, 2019-2025
26 companies · $287 in 2025
The $287 reported for 2025 was more than what 75% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $242 · 2021: $213 · 2022: $76.04 · 2023: $114 · 2024: $563 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.50 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $156.24 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $138.90 | 2019-2021 | |
| Novo Nordisk INC | $105.84 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $104.64 | 2021-2024 | Airsupra, Breztri |
| Exact Sciences Corporation | $90.78 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $89.31 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.87 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $80.62 | 2019-2021 | |
| Janssen Biotech, INC. | $76.27 | 2024-2025 | Erleada, Akeega |
| Abbvie INC. | $74.65 | 2021-2024 | |
| Teleflex LLC | $60.45 | 2025 | Barrigel, Urolift |
| Boston Scientific Corporation | $50.89 | 2024-2025 | Ams 700, Bulkamid |
| Amarin Pharma, INC. | $48.42 | 2020 | |
| Sanofi Pasteur INC. | $47.53 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.62 | 2024 | Shingrix |
| Gilead Sciences, INC. | $33.00 | 2022 | |
| Olympus America INC. | $27.69 | 2024 | Itind System |
| Sumitomo Pharma America, INC. | $25.85 | 2024 | Orgovyx |
| Abc Home Medical Supply, INC. | $24.71 | 2025 | |
| Idorsia Pharmaceuticals US INC | $23.80 | 2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $20.16 | 2021 | |
| Abbott Laboratories | $20.10 | 2022 | |
| Becton, Dickinson and Company | $19.75 | 2023 | Bd Onclarity |
| Takeda Pharmaceuticals U.S.A., INC. | $18.75 | 2023 | Cuvitru |
| Advanced Respiratory, INC | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artemio Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.